Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

1.

[A multicenter study on the validation of conversion factor for the conversion of BCR-ABL (P210) transcript levels to the international scale in chronic myeloid leukemia].

Qin Y, Lin Z, Cen J, Li X, Li Q, Cheng H, Geng S, Wang Y, Ma D, Qiao C, Li J, Li L, Huang X.

Zhonghua Xue Ye Xue Za Zhi. 2014 Feb;35(2):134-7. doi: 10.3760/cma.j.issn.0253-2727.2014.02.016. Chinese.

PMID:
24606655
[PubMed - in process]
Free Article
2.

[A multicenter comparison study on the quantitative detection of bcr-abl (P210) transcript levels in China].

Qin YZ, Cheng H, Cen JN, Geng SX, Li QH, Li XQ, Lin ZX, Ma DX, Qiao C, Wang YG, Li JL, Li LD, Huang XJ.

Zhonghua Xue Ye Xue Za Zhi. 2013 Feb;34(2):104-8. Chinese.

PMID:
23611214
[PubMed - indexed for MEDLINE]
Free Article
3.

Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan.

Yoshida C, Fletcher L, Ohashi K, Wakita H, Kumagai T, Shiseki M, Matsuei K, Inokuchi K, Hatta Y, Shirasugi Y, Yamaguchi T, Sakamoto J, Branford S, Sakamaki H.

Int J Clin Oncol. 2012 Dec;17(6):584-9. doi: 10.1007/s10147-011-0328-x. Epub 2011 Oct 12.

PMID:
21986632
[PubMed - indexed for MEDLINE]
4.

p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.

van Rhee F, Hochhaus A, Lin F, Melo JV, Goldman JM, Cross NC.

Blood. 1996 Jun 15;87(12):5213-7.

PMID:
8652835
[PubMed - indexed for MEDLINE]
Free Article
5.

[Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].

Zhu XZ, Yu YZ, Fang YM, Liang Y, Lü QH, Xu RZ.

Zhonghua Yi Xue Za Zhi. 2005 Jul 20;85(27):1903-6. Chinese.

PMID:
16255985
[PubMed - indexed for MEDLINE]
6.

Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210(BCR-ABL) and p190(BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190(BCR-ABL) detection precede cytogenetic relapse.

Serrano J, Roman J, Sanchez J, Jimenez A, Castillejo JA, Herrera C, Gonzalez MG, Reina L, Rodriguez MC, Alvarez MA, Maldonado J, Torres A.

Blood. 2000 Apr 15;95(8):2659-65.

PMID:
10753848
[PubMed - indexed for MEDLINE]
Free Article
7.

BCR/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML).

Arana-Trejo RM, Ruíz Sánchez E, Ignacio-Ibarra G, Báez de la Fuente E, Garces O, Gómez Morales E, Castro Granados M, Ovilla Martínez R, Rubio-Borja ME, Solís Anaya L, Herrera P, Delgado Llamas J, Kofman S.

Clin Lab Haematol. 2002 Jun;24(3):145-50.

PMID:
12067277
[PubMed - indexed for MEDLINE]
8.

Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia.

Lichty BD, Keating A, Callum J, Yee K, Croxford R, Corpus G, Nwachukwu B, Kim P, Guo J, Kamel-Reid S.

Br J Haematol. 1998 Dec;103(3):711-5.

PMID:
9858221
[PubMed - indexed for MEDLINE]
9.

[The mechanism of apoptosis of chronic myeloid leukemia cells induced by the novel p210 bcr/abl inhibitor berbamine].

Sun JR, Zhang XH, He ZW, Gu Y, Yu YZ, Fang YM, Lü QH, Dong QH, Xu RZ.

Zhonghua Yi Xue Za Zhi. 2006 Aug 29;86(32):2246-51. Chinese.

PMID:
17064567
[PubMed - indexed for MEDLINE]
10.

The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene.

Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D.

Science. 1986 Jul 11;233(4760):212-4.

PMID:
3460176
[PubMed - indexed for MEDLINE]
11.

Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.

Román J, Alvarez MA, Torres A.

Haematologica. 2000 Oct;85(10):1072-82. Review.

PMID:
11025600
[PubMed - indexed for MEDLINE]
Free Article
12.

Validation of the 2-DeltaDeltaCt calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts.

Arocho A, Chen B, Ladanyi M, Pan Q.

Diagn Mol Pathol. 2006 Mar;15(1):56-61.

PMID:
16531770
[PubMed - indexed for MEDLINE]
13.

p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells.

Chang YC, Tien SC, Tien HF, Zhang H, Bokoch GM, Chang ZF.

Oncogene. 2009 Nov 19;28(46):4105-15. doi: 10.1038/onc.2009.260. Epub 2009 Aug 31.

PMID:
19718053
[PubMed - indexed for MEDLINE]
14.

The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.

Li S, Ilaria RL Jr, Million RP, Daley GQ, Van Etten RA.

J Exp Med. 1999 May 3;189(9):1399-412.

PMID:
10224280
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

[Detection of common fusion transcript levels in untreated leukemia patients by real-time quantitative RT-PCR technique].

Qin YZ, Li JL, Zhu HH, Li LD, Chang Y, Le H, Ruan GR, Liu YR, Huang XJ, Chen SS.

Zhonghua Xue Ye Xue Za Zhi. 2007 Jul;28(7):433-7. Chinese.

PMID:
18072623
[PubMed - indexed for MEDLINE]
16.

Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.

Matulonis U, Salgia R, Okuda K, Druker B, Griffin JD.

Exp Hematol. 1993 Oct;21(11):1460-6.

PMID:
8405226
[PubMed - indexed for MEDLINE]
17.

[Effects of bcr/abl fusion gene on expression of beta1 integrin and L-selectin in mouse chronic myeloid leukemia cells].

Wang WL, Shen T, Hui YR, Gu XC, Li RS.

Zhonghua Xue Ye Xue Za Zhi. 2003 Jul;24(7):337-9. Chinese.

PMID:
12941184
[PubMed - indexed for MEDLINE]
18.

Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.

Gross AW, Ren R.

Oncogene. 2000 Dec 14;19(54):6286-96.

PMID:
11175343
[PubMed - indexed for MEDLINE]
Free Article
19.

International reporting scale of BCR-ABL1 fusion transcript in chronic myeloid leukemia: first report from India.

Balasubramanian P, Chendamarai E, Markose P, Fletcher L, Branford S, George B, Mathews V, Chandy M, Srivastava A.

Acta Haematol. 2012;127(3):135-42. doi: 10.1159/000334716. Epub 2012 Jan 12.

PMID:
22249155
[PubMed - indexed for MEDLINE]
20.

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

Branford S, Fletcher L, Cross NC, Müller MC, Hochhaus A, Kim DW, Radich JP, Saglio G, Pane F, Kamel-Reid S, Wang YL, Press RD, Lynch K, Rudzki Z, Goldman JM, Hughes T.

Blood. 2008 Oct 15;112(8):3330-8. doi: 10.1182/blood-2008-04-150680. Epub 2008 Aug 6.

PMID:
18684859
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk